Bronchopulmonary Dysplasia Clinical Trial
Official title:
Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes
Verified date | November 2023 |
Source | Nationwide Children's Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
Patent ductus arteriosus (PDA), very common in preterm infants, is the delayed closure of a fetal blood vessel that limits blood flow through the lungs. PDA is associated with mortality and harmful long term outcomes including chronic lung disease and neurodevelopmental delay. Although, treatments to close PDA likely benefit some infants, widespread routine treatment of all preterm infants with PDA may not improve important outcomes. Left untreated, most PDAs close spontaneously. Thus, PDA treatment is increasingly controversial and varies markedly between hospitals and individual providers. The relevant and still unanswered clinical question is not whether to treat all preterm infants with PDA, but whom to treat and when. Treatment detriments may outweigh benefits, since all forms of deliberate PDA closure have potential adverse effects, especially in infants destined for early, spontaneous PDA closure. Unfortunately, clinicians cannot currently predict in the 1st month which infants are at highest risk for persistent PDA, and which combination of clinical risk factors, echocardiographic (echo) measurements, and serum biomarkers may best predict PDA-associated harm. The American Academy of Pediatrics has acknowledged early identification of infants at high-risk from PDA as a key research goal for informing future PDA-treatment effectiveness trials. Our objective is to use a prospective cohort of untreated infants with PDA to predict spontaneous ductal closure timing and identify echo measurements and biomarkers that are present in the 1st postnatal month and associated with long-term impairment. Our central hypothesis is that these risk factors can be determined to inform appropriate clinical treatments when necessary. Clinical, serum and urine biomarkers (BNP, NTpBNP, NGAL, H-FABP), and echo variables sequentially collected during each of the first 4 postnatal weeks will be examined. In addition myocardial deformation imaging (MDI) and tissue Doppler imaging (TDI), innovative echo methods, will facilitate the quantitative evaluation of myocardial performance. Aim 1 will estimate the probability of spontaneous PDA closure and predict the timing of ductal closure using echo, biomarker, and clinical predictors. Aim 2 will specify which echo predictors and biomarkers are associated with mortality and severity of respiratory illness at 36-weeks PMA. Aim 3 will identify which echo predictors and biomarkers are associated with 22- to 26-month neurodevelopment. All models will be validated in a separate cohort. This project will significantly contribute to clinical outcomes and PDA management by reducing unnecessary and harmful overtreatment of infants with a high probability of early spontaneous PDA closure, and will permit the development of outcomes-focused trials to examine the effectiveness of PDA closure in those "high-risk" infants most likely to receive benefit.
Status | Active, not recruiting |
Enrollment | 675 |
Est. completion date | June 2026 |
Est. primary completion date | March 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 72 Hours |
Eligibility | Inclusion Criteria: - Born between 23-weeks + 0 days (23_0/7 wks) and 29-weeks + 6 days (29_6/7 wks) gestation, inclusive - Admitted to a study neonatal intensive care unit (NICU) within 72-hours of birth - PDA noted on initial screening echo at <72 postnatal hours Exclusion Criteria: - Life-threatening congenital abnormalities, including congenital heart disease (other than PDA or small atrial septal defects/patent foramen ovale/muscular VSD) - Parents have chosen to allow natural death (placed a do not resuscitate order) |
Country | Name | City | State |
---|---|---|---|
United States | Nationwide Children's Hospital Main Campus Neonatal Intensive Care Unit | Columbus | Ohio |
United States | Nationwide Children's Hospital Neonatal Intensive Care Unit at OhioHealth Grant Medical Center | Columbus | Ohio |
United States | Nationwide Children's Neonatal Intensive Care Unit at OhioHealth Riverside Methodist Hospital | Columbus | Ohio |
United States | Nationwide Children's Neonatal Intensive Care Unit at The Ohio State University Wexner Medical Center | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
Nationwide Children's Hospital | Mount Carmel Health System, National Heart, Lung, and Blood Institute (NHLBI), Ohio State University, OhioHealth |
United States,
Benitz WE; Committee on Fetus and Newborn, American Academy of Pediatrics. Patent Ductus Arteriosus in Preterm Infants. Pediatrics. 2016 Jan;137(1). doi: 10.1542/peds.2015-3730. Epub 2015 Dec 15. — View Citation
Pavlek LR, Slaughter JL, Berman DP, Backes CH. Catheter-based closure of the patent ductus arteriosus in lower weight infants. Semin Perinatol. 2018 Jun;42(4):262-268. doi: 10.1053/j.semperi.2018.05.009. Epub 2018 Jun 13. — View Citation
Slaughter JL, Reagan PB, Newman TB, Klebanoff MA. Comparative Effectiveness of Nonsteroidal Anti-inflammatory Drug Treatment vs No Treatment for Patent Ductus Arteriosus in Preterm Infants. JAMA Pediatr. 2017 Mar 6;171(3):e164354. doi: 10.1001/jamapediatrics.2016.4354. Epub 2017 Mar 6. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Normal cardiac function at 36-weeks PMA (binary) | No functional abnormalities identified on the 36-week echocardiogram, as read by the study cardiologist | Recorded at 36-weeks PMA or discharge if prior to 36-weeks | |
Other | Quantitative myocardial deformation imaging (MDI) at 36-weeks PMA (continuous) | Recorded at 36-weeks PMA or discharge if prior to 36-weeks | ||
Other | Quantitative tissue Doppler imaging (TDI) at 36-weeks PMA (continuous) | Recorded at 36-weeks PMA or discharge if prior to 36-weeks | ||
Other | Pulmonary Hypertension at 36-weeks PMA (binary) | Pulmonary hypertension noted on the 36-week echocardiogram, as read by the study cardiologist | Recorded at 36-weeks PMA or discharge if prior to 36-weeks | |
Other | Normal left atrial size at 36-weeks PMA (binary) | No left atrial enlargement identified on the 36-week echocardiogram, as read by the study cardiologist | Recorded at 36-weeks PMA or discharge if prior to 36-weeks | |
Other | Normal left ventricular size at 36-weeks PMA (binary) | No left ventricular enlargement identified on the 36-week echocardiogram, as read by the study cardiologist | Recorded at 36-weeks PMA or discharge if prior to 36-weeks | |
Other | Normal right ventricular size at 36-weeks PMA (binary) | No right ventricular enlargement identified on the 36-week echocardiogram, as read by the study cardiologist | Recorded at 36-weeks PMA or discharge if prior to 36-weeks | |
Other | Oxygen Dependency (Moderate BPD) (binary) | Recorded at 36-weeks PMA | ||
Other | Positive-Pressure Dependency (Severe BPD) (binary) | Recorded at 36-weeks PMA | ||
Other | Length at 36-weeks PMA | Length in centimeters | Recorded at 36-weeks PMA or discharge if prior to 36-weeks | |
Other | General Movements Assessment (GMA) at 36-weeks corrected age | Prechtl's method for the qualitative assessment of general movements dysfunction | Recorded at 36-weeks PMA | |
Other | Time to enteral feed initiation | 72 hours postnatal to 36-weeks PMA | ||
Other | Time to a full enteral feed diet | Infant is weaned from intravenous fluids to a full enteral feed diet (delivery of feeds may be via an enteric tube) | 72 hours postnatal to 36-weeks PMA | |
Other | Oral feeding status (binary) | Infant is taking all feeds by mouth (PO feeds) by 36-weeks PMA | Recorded at 36-weeks PMA | |
Other | Weight at 36-weeks PMA | Weight in grams | Recorded at 36-weeks PMA or discharge if prior to 36-weeks | |
Other | Occipitofrontal circumference (OFC) at 36-weeks PMA | OFC in centimeters | Recorded at 36-weeks PMA or discharge if prior to 36-weeks | |
Other | Body Mass Index (BMI) at 36-weeks PMA | BMI calculated by (BMI= weight in kg/length in meters squared) | Recorded at 36-weeks PMA or discharge if prior to 36-weeks | |
Other | Supplemental oxygen or positive-pressure respiratory support at 40-weeks PMA (binary) | Recorded at 40-weeks PMA | ||
Other | Mortality by 22-26 months corrected age | Death occuring between 72-hours postnatal and 22-26 months corrected age | ||
Other | Duration of ductal patency from 72-hours postnatal until 22 to 26-months corrected age follow-up | 72 hours postnatal until 22-26 months follow-up visit | ||
Other | Supplemental oxygen support (binary) at 22-26 months corrected age | Recorded at 22-26 months study follow-up visit | ||
Other | Supplemental positive-pressure ventilation support (binary) at 22-26 months corrected age | Recorded at 22-26 months study follow-up visit | ||
Other | Weight at 22-26 months corrected age | Weight in kilograms | Recorded at 22-26 months study follow-up visit | |
Other | Length at 22-26 months corrected age | Length in centimeters | Recorded at 22-26 months study follow-up visit | |
Other | Body Mass Index (BMI) at 22-26 months corrected age | BMI calculated by (BMI= weight in kg/length in meters squared) | Recorded at 22-26 months study follow-up visit | |
Other | Feeding status via full oral feeding or gastric-tube (binary) at 22-26 months corrected age | Recorded at 22-26 months study follow-up visit | ||
Primary | Patent ductus arteriosus (PDA) closure documented via echocardiogram by 36-weeks postmenstrual age (PMA) (binary) | Documented closure of PDA on echocardiogram. Echocardiograms to document the primary outcome will be conducted weekly for the first four postnatal weeks and every other week thereafter, between study entry and 36-weeks PMA until PDA-closure is documented | Outcome will be documented between <72-hour screening echo and 36-weeks PMA. | |
Primary | Mortality or supplemental oxygen or positive-pressure respiratory support at 36-weeks PMA (binary) | Death occurring between study entry at <72-hours postnatal and 36-weeks PMA OR an oxygen or positive-pressure ventilation requirement at 36-weeks gestational age (=moderate bronchopulmonary dysplasia [BPD] or severe BPD) | Outcome will be documented between <72-hour screening echo and 36-weeks PMA | |
Primary | Composite Bayley III Motor Score at 22-26 months corrected age (continuous) | Composite motor score at 22 to 26-months postnatal as measured by Bayley Scales of Infant and Toddler Development- 3rd Edition (Bayley III) | Bayley III Score Testing will occur at 22 to 26 months corrected age (CA) (age since birth - number of weeks born before 40-weeks gestation) | |
Secondary | Mortality by 36-weeks PMA (binary) | Death occuring between 72-hours postnatal and 36-weeks PMA | ||
Secondary | Bayley III Gross Motor Development Scaled Standard Score at 22-26 months corrected age (continuous) | Recorded at 22-26 months corrected age | ||
Secondary | Bayley III Fine Motor Development Scaled Standard Score postnatal age at 22-26 months corrected age (continuous) | Recorded at 22-26 months corrected age | ||
Secondary | Bayley III Cognitive Composite Score at 22-26 months corrected age (continuous) | Recorded at 22-26 months corrected age | ||
Secondary | Bayley III Language Composite Score at 22-26 months corrected age (continuous) | Recorded at 22-26 months corrected age |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04506619 -
Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants
|
||
Completed |
NCT04936477 -
Ventilation-perfusion (V/Q) Ratio and Alveolar Surface Area in Preterm Infants
|
N/A | |
Recruiting |
NCT05285345 -
Implementation of a Consensus-Based Discharge Protocol for Preterm Infants With Lung Disease
|
||
Completed |
NCT03649932 -
Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing
|
Phase 1 | |
Terminated |
NCT02524249 -
Early Versus Late Caffeine for ELBW Newborns
|
N/A | |
Completed |
NCT02249143 -
Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants
|
N/A | |
Active, not recruiting |
NCT01632475 -
Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia
|
||
Completed |
NCT01460576 -
Improving Prematurity-Related Respiratory Outcomes at Vanderbilt
|
N/A | |
Unknown status |
NCT00254176 -
Cysteine Supplementation in Critically Ill Neonates
|
Phase 2/Phase 3 | |
Completed |
NCT00419588 -
Growth of Airways and Lung Tissues in Premature and Healthy Infants
|
||
Completed |
NCT00319956 -
Trial II of Lung Protection With Azithromycin in the Preterm Infant
|
Phase 2 | |
Completed |
NCT00208039 -
Pilot Trial of Surfactant Booster Prophylaxis For Ventilated Preterm Neonates
|
N/A | |
Completed |
NCT00006401 -
Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants
|
Phase 3 | |
Terminated |
NCT05030012 -
Maintaining Optimal HVNI Delivery Using Automatic Titration of Oxygen in Preterm Infants
|
N/A | |
Completed |
NCT00006058 -
Study of the Pathobiology of Bronchopulmonary Dysplasia in Newborns
|
N/A | |
Completed |
NCT00005376 -
Premature Birth and Its Sequelae in Women
|
N/A | |
Completed |
NCT00011362 -
Dexamethasone Therapy in VLBW Infants at Risk of CLD
|
Phase 3 | |
Completed |
NCT00004805 -
Study of the Effect of Four Methods of Cardiopulmonary Resuscitation Instruction on Psychosocial Response of Parents With Infants at Risk of Sudden Death
|
N/A | |
Completed |
NCT05152316 -
The Baby Lung Study
|
||
Recruiting |
NCT04821453 -
NAVA vs. CMV Crossover in Severe BPD
|
N/A |